NEW YORK, June 16, 2000 (PRIMEZONE) -- Thirteen leading analysts and top management from ninety-seven sector firms examine Investing Strategies in this special 364-page U.S. Bancorp Piper Jaffray Conference Issue from The Wall Street Transcript (212/952-7433) or http://www.twst.com/info/info114.htm.
1) Biotechnology Stocks - In an in-depth (3,600 words) Analyst Interview, Mark Augustine, Senior Research Analyst with U.S. Bancorp Piper Jaffray's Equity Research Group, examines the outlook for the sector, including the DSL niche, optical networking technology, mergers and acquisitions activity, and shares specific stock recommendations.
Augustine explains his group's approach to the biotech sector. "As with many other sectors covered by our firm, we have decided to divide things up, and in this case, along the lines of disease focus. I have spent considerable time over the last 10 years in infectious disease, autoimmune/inflammatory disease, and cardiovascular disease as well as specialty and vaccine companies. The names that I look at in these areas are generally product-based companies."
Augustine labels MedImmune (Nasdaq:MEDI) an exciting story. "This is because there is no competition in sight and the fact that it addresses a compelling medical need and the company will be able to leverage its flagship product into other patient populations, such as the elderly and the less severely premature, and generate, we believe, a 30% sustainable earnings growth rate."
Augustine highlights Aviron (Nasdaq:AVIR). "Another approach to prevention that stands, we believe, to be approved next year is a novel intranasal influenza vaccine. That's a product out of a pure-play vaccine company called Aviron in Mountain View, California. We see a 2001 approval and launch for an important product here that has $600 million in peak worldwide sales potential."
BioChem Pharma (Nasdaq:BCHE) is on the rebound, according to Augustine. "Zeffix sales have begun to accelerate and BioChem Pharma, an unbelievably cheap stock, might actually be a stock in rebound this year as Zeffix sales accelerate and they get an interesting cancer drug, troxacitabine, through Phase II studies. We project a 31% five-year earnings growth."
Alexion (Nasdaq:ALXN) is an exciting company, according to Augustine. "Alexion is developing novel anti-inflammatory drugs that inhibit complement proteins. If there is positive news in any one of these Phase II studies, we think the stock could double. They've got an outstanding management team, and it's perhaps the most exciting earlier stage biotech company that we're focusing people on at this point."
This 364-page U.S. Bancorp Piper Jaffray Conference Issue also features:
2) Outlook for U.S. Bancorp Piper Jaffray - In an in-depth (1,600 words) Analyst Interview, Thomas Schreier, Managing Director of U.S. Bancorp Piper Jaffray, examines the outlook for the five sectors he covers, and highlights the theme of this year's conference.
3) IT Infrastructure - In an in-depth (1,100 words) Analyst Interview, Ashok Kumar, Managing Director of U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including investment strategies, demand/supply issues, new technology applications, and shares specific stock recommendations.
4) Wireless Communications Stocks - In an in-depth (2,300 words) Analyst Interview, Samuel May, Managing Director of U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including investment strategies, sector trends, the mobile internet, the U.S. Bancorp Piper Jaffray Wireless Index, and shares specific stock recommendations.
5) Internet Software Infrastructure - In an in-depth (3,400 words) Analyst Interview, Hany Nada, Managing Director of U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including e-commerce, trends on the demand side, his valuation methodology, and shares specific stock recommendations.
6) B2B E-Commerce - In an in-depth (4,100 words) Analyst Interview, Jon Ekoniak, Vice President with U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including e-commerce, various business models in the sector, and shares specific stock recommendations.
7) Outlook for Electronic Commerce - In an in-depth (3,900 words) Analyst Interview, Stephen Franco, Vice President with U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including e-commerce, online financial services, investment trends, and shares specific stock recommendations.
8) Network Infrastructure - In an in-depth (1,800 words) Analyst Interview, Conrad Leifur, Vice President with U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including the DSL niche, optical networking technology, mergers and acquisitions activity, and shares specific stock recommendations.
9) Financial Business Services - In an in-depth (4,500 words) Analyst Interview, Bradley Berning, Senior Research Analyst at U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including common characteristics of Financial Business Services companies, investment themes or trends, and shares specific stock recommendations.
10) Healthcare Services - In an in-depth (3,700 words) Analyst Interview, William Bonello, Senior Research Analyst at U.S. Bancorp Piper Jaffray, examines the outlook for the sector, including reimbursement basis for Healthcare Services companies, trends in reimbursement, and shares specific stock recommendations.
11) Lifestyle Retailing - In an in-depth (3,700 words) Analyst Interview, Jeffrey Klinefelter, Senior Research Analyst at U.S. Bancorp Piper Jaffray, explains the concept of lifestyle retailing, examines the outlook for the sector, and shares specific stock recommendations.
12) Outlook for E-Health - In an in-depth (2,600 words) Analyst Interview, Daren Marhula, Senior Research Analyst at U.S. Bancorp Piper Jaffray, examines the outlook for the sector on the business-to-consumer and on the B2B side, and shares specific stock recommendations.
13) Retail Hardlines Stocks - In an in-depth (4,000 words) Analyst Interview, Rebecca Yarchover, Senior Research Analyst at U.S. Bancorp Piper Jaffray's Equity Research Group, examines the outlook for the sector, including retail hardlines companies, consumer electronics, and shares specific stock recommendations.
14) CEO/Company Interviews - Top management of ninety-seven sector firms examine the outlook for their firm and the sector. Firms include:
AmeriCredit, Bridge Medical, Cintas, click2learn.com, Community First Bankshares, Delano Technology, Equifax, Harris Interactive, HEALTHSOUTH, IntraNet Solutions, JDS Uniphase, Layton BioScience, Lightspan, Lionbridge Technologies, Metris Companies, Multex.com, National Discount Brokers Group, OraPharma, RADVision Ltd., Retek, 99 Cents Only Stores, Abercrombie & Fitch Company, ADC Telecommunications, Allos Therapeutics, Alloy Online, American Dental Partners, American Express Company, AmeriPath, Applebee's International, Aspect Communications, Bluefly, C.H. Robinson Worldwide, Clarus, Coldwater Creek, Commerce One, Confer Software, Davox, Ecolab, Electronics for Imaging, Eloquent, ePocrates, E-Tek Dynamics, Expeditors International of Washington, Family Dollar Stores, Fidelity National Financial, Gateway, Go2Net, Guitar Center, H.B. Fuller Company, Hanger Orthopedic Group, Heller Financial, HomeServices.com, Hormel Food Corp., iManage, Insight Enterprises, Interactive Intelligence, iVillage, Landec, Liberate Technologies, LookSmart Ltd., Macrovision, MCK Communications, MedChannel, Media 100, Metron Technology NV, Michael Foods, Mortgage.com, National Instruments, Natrol, Netcentives, NETsilicon, Network Commerce, NextCard, Nu Skin Enterprises, Online Resources & Communications, OrthAlliance, Performance Food Group, Pinnacle Systems, Primus Telecommunications Group, Redback Networks, Regis, RehabCare Group, Restoration Hardware, School Speciality, SelfCare.com, SimplyHealth.com, Spiegel, Splash Technology Holdings, Starbucks, T/R Systems, TCF Financial, TMP Worldwide, Tuesday Morning, U.S. Bancorp, Uno Restaurant, Witness Systems, Xchange.
To obtain a copy of this 364-page U.S. Bancorp Piper Jaffray Conference Issue, call (212) 952-7433 or see http://www.twst.com/info/info114.htm.
The Wall Street Transcript is a premier weekly investment publication interviewing market professionals for serious investors for over 37 years.
The Wall Street Transcript has launched a new free service where investors can ask any of the above companies (or any public company) a question at http://www.qawire.com.
The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.